Skip to main content

Liver Diseases

The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.

Team

Maria Buti Ferret

Maria Buti Ferret

Main researcher
Liver Diseases
Read more
Maria del Mar Riveiro Barciela

Maria del Mar Riveiro Barciela

Main researcher
Liver Diseases
Read more
Meritxell Ventura Cots

Meritxell Ventura Cots

Main researcher
Liver Diseases
Read more
Monica Higuera Urbano

Monica Higuera Urbano

Research technician
Liver Diseases
Read more
Mònica Pons Delgado

Mònica Pons Delgado

Predoctoral researcher
Liver Diseases
Read more
Montserrat Gomez Perez

Montserrat Gomez Perez

Liver Diseases
Read more
Maria Buti Ferret

Maria Buti Ferret

Main researcher
Liver Diseases
Read more
Maria del Mar Riveiro Barciela

Maria del Mar Riveiro Barciela

Main researcher
Liver Diseases
Read more
Meritxell Ventura Cots

Meritxell Ventura Cots

Main researcher
Liver Diseases
Read more
Monica Higuera Urbano

Monica Higuera Urbano

Research technician
Liver Diseases
Read more
Mònica Pons Delgado

Mònica Pons Delgado

Predoctoral researcher
Liver Diseases
Read more
Montserrat Gomez Perez

Montserrat Gomez Perez

Liver Diseases
Read more

Projects

Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular

IP: Beatriz Minguez Rosique
Collaborators: Itxarone Izaskun Bilbao Aguirre, Elena Vargas Accarino, Maria Teresa Salcedo Allende, Monica Higuera Urbano
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI21/00714
Duration: 01/01/2022 - 31/12/2025

D-Mongolia: screening and linkage-to-care for Hepatitis D in Mongolian nationals living in Spain - Modalitat hepatitis

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 48763
Reference: GLD21_00139
Duration: 30/06/2022 - 31/10/2024

Publications

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.

PMID: 37884354
Journal: GUT
Year: 2023
Reference: Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
Impact factor:
Publication type: Paper in international publication
Authors: Abraldes, Juan G; Agueras, Cajal; Alessandria, Carlo; Allegretti, Andrew S; Alonso, Sonia; Asrani, Sumeet K; Beuers, Ulrich; Campion, Daniela; Caraceni, Paolo; de Wit, Koos et al.
DOI: 10.1136/gutjnl-2023-329923

Hierarchical Cluster Analysis Based on Clinical and Neuropsychological Symptoms Reveals Distinct Subgroups in Fibromyalgia: A Population-Based Cohort Study.

PMID: 37893239
Journal: Biomedicines
Year: 2023
Reference: Biomedicines. 2023 Oct 23;11(10):2867. doi: 10.3390/biomedicines11102867.
Impact factor:
Publication type: Paper in international publication
Authors: Aban, M; Abraldes, Juan G; Alegre-Martin, Jose; Alessandria, Carlo; Allegretti, Andrew S; Alonso, Sonia; Andrade, R; Angeli, P; Asrani, Sumeet K; Avitabile, E et al.
DOI: 10.3390/biomedicines11102867

Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.

PMID: 37896223
Journal: Pharmaceutics
Year: 2023
Reference: Pharmaceutics. 2023 Oct 14;15(10):2463. doi: 10.3390/pharmaceutics15102463.
Impact factor:
Publication type: Paper in international publication
Authors: Abasolo, Ibane; Agarwal, Neeraj; Andrade, Fernanda; Azad, Arun A; Chakrabarti, Jayeta; Chen, Hsiang-Chun; Fizazi, Karim; Genesca, Joan; Gil, Mar; Hide, Diana et al.
DOI: 10.3390/pharmaceutics15102463

The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study).

PMID: 37892611
Journal: Journal of Clinical Medicine
Year: 2023
Reference: J Clin Med. 2023 Oct 11;12(20):6471. doi: 10.3390/jcm12206471.
Impact factor:
Publication type: Paper in international publication
Authors: Abe, Hiroshi; Ahn, Sang Bong; Aldea-Perona, Ana; An, Jihyun; Arai, Taeang; Atsukawa, Masanori; Avendano-Sola, Cristina; Blasco Quilez, Maria Rosario; Bonilla-Toyos, Elvira; Bosch Ferrer, Montserrat et al.
DOI: 10.3390/jcm12206471

Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study.

PMID: 35487453
Journal: Clinical Gastroenterology and Hepatology
Year: 2022
Reference: Clin Gastroenterol Hepatol. 2022 Apr 26. pii: S1542-3565(22)00403-7. doi: 10.1016/j.cgh.2022.03.050.
Impact factor: 11.382
Publication type: Paper in international publication
Authors: Riveiro-Barciela, Mar, Barreira-Diaz, Ana, Callejo-Perez, Ana, Munoz-Couselo, Eva, Diaz-Mejia, Nely, Diaz-Gonzalez, Alvaro, Londono, Maria-Carlota, Salcedo, Maria-Teresa, Buti, Maria et al.
DOI: 10.1016/j.cgh.2022.03.050

Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2.

PMID: 35453934
Journal: Diagnostics
Year: 2022
Reference: Diagnostics (Basel). 2022 Apr 1;12(4). pii: diagnostics12040886. doi: 10.3390/diagnostics12040886.
Impact factor: 3.706
Publication type: Paper in international publication
Authors: Gabriel-Medina, Pablo, Diaz-Troyano, Noelia, Barquin-DelPino, Raquel, Castillo-Ribelles, Laura, Esteban, Angels, Hernandez-Gonzalez, Manuel, Ferrer-Costa, Roser, Pumarola, Tomas, Rodriguez-Frias, Francisco, Klammer, Martin et al.
DOI: 10.3390/diagnostics12040886

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.

PMID: 34964311
Journal: Hepatology Communications
Year: 2022
Reference: Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28.
Impact factor: 5.073
Publication type: Paper in international publication
Authors: Esnault, V, Pose, Elisa, Sola, Elsa, Lozano, Juan J, Juanola, Adria, Sidorova, Julia, Zaccherini, Giacomo, Giovo, I, Roux, O, Simon-Talero, M et al.
DOI: 10.1002/hep4.1881

Changes in Parvovirus B19 positivity rates in plasma units for fractionation: An unexpected effect of non-pharmaceutical interventions against COVID-19?

PMID: 34877666
Journal: VOX SANGUINIS
Year: 2022
Reference: Vox Sang. 2022 Apr;117(4):626-627. doi: 10.1111/vox.13229. Epub 2021 Dec 8.
Impact factor: 2.144
Publication type: Letter or abstract
Authors: Sauleda, Silvia, Piron, Maria, Bes, Marta, Martinez-Llonch, Nuria, Puig, Lluis et al.
DOI: 10.1111/vox.13229

Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.

PMID: 28051797
Journal: Annals of Hepatology
Year: 2017
Reference: Ann Hepatol. 2017 Jan-Feb 2017;16(1):86-93. doi: 10.5604/16652681.1226819.
Impact factor: 1.678
Publication type: Paper in international publication
Authors: Salcedo, Teresa, Esteban, Juan Ignacio, Esteban-Mur, Rafael, Charco, Ramon, Rodriguez-Frias, Francisco, Len, Oscar, Crespo, Manel, Castells, Lluis, Llaneras, Jordi, Campos-Varela, Isabel et al.
DOI: 10.5604/16652681.1226819

Blog

News

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Estudi sobre els patrons de consum habitual de l'alcohol en població jove

Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.

Més informació